Peptide appearance
Lyophilized form helps protect peptide quality. Peptides are supplied as a dry powder, which may look like a compact "puck" or a lighter powder inside the vial.
Because the peptide is dry, it does not require refrigerated shipping during normal transit, including warm seasonal conditions. For longer storage, follow the storage guidance in the product description.
Appearance can vary. The stated peptide content is checked through third-party analysis.
Read more in the product description.
Solution not bundled
Peptides are delivered as lyophilized powder. This dry form helps preserve peptide quality during storage and transport and does not require refrigerated shipping during normal transit.
To prepare a solution, use a solvent such as Bacteriostatic water. It is sold separately, so add it only when you need it for peptide preparation.
Read more in the product description.
Metabolic Research
GLP-3 (RT)
In stock
GLP-3 is Adria Science's catalogue name for retatrutide. This synthetic peptide is studied at GIP, GLP-1, and glucagon receptors.
Order within — · ships today Cutoff 10:00 · local time
Arrives Oct 7 - Oct 9 to Europe
Shown at checkout
GLP-3 (RT)
Price range: 77,90 € through 168,50 €
Triple incretin analogue for GLP-1, GIP, and glucagon receptor pathway studies.
Research overview
GLP-3 (RT)
Retatrutide, also called LY3437943, is one engineered peptide that can signal through three receptor pathways. Its design is different from a blend of separate peptides.
Studies measure receptor activity, glucose-related signals, fat-tissue endpoints, and liver models. These controlled findings do not promise a result for the supplied material.
Triple-receptor pharmacology
Studies measure activity at GIP, GLP-1, and glucagon receptors. They also examine sequence design and albumin binding.
The three pathways are not interchangeable. Comparisons must use the exact assay and activity values from the original study.
Metabolic and liver models
Published work also covers glucose, lipid, energy-balance, and liver-related measurements. These findings do not replace lot-specific analytical testing.
Compound information
Specifications
Molecular profile
- Sequence
- Y-Aib-QGTFTSDYSI-alphaMeLeu-LDKK(AEEA-gamma-Glu-C20 diacid)-AQAibAFIEYLLEGGPSSGAPPPS-NH2
- Molecular mass
- 4731.4 g/mol
- CAS number
- 2381089-83-2
- Molecular formula
- C221H342N46O68
Material record
- Physical appearance
- White to off-white lyophilized powder
- Solubility
- Soluble in bacteriostatic water and suitable aqueous laboratory solvents.
- Product note
- GLP-3 research compound; supplied strictly for research use only.
Laboratory care
Handling
Peptides in transport
Peptides in lyophilized form are supplied in glass vials by standard shipping methods and do not require refrigeration. Short-term temperature fluctuations during transport will not reduce their quality and efficacy. Even at high summer temperatures, the peptides in lyophilized form are stable for several weeks.
Storage of lyophilized peptides
Lyophilized peptides should be stored in a dry place, protected from light and moisture. The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Up to 3 months
- Refrigerated (2–8 °C): Up to 6 months
- Frozen (-20 °C or below): 3–5 years (recommended for long-term storage)
Allow the vial to reach room temperature after taking it out of the refrigerator or freezer.
Storage of reconstituted peptides
Once reconstituted, peptide solutions are generally less stable than their lyophilized form and should be stored under refrigerated conditions whenever possible.
The following storage conditions are generally recommended:
- Room temperature (15–25 °C): Avoid prolonged storage
- Refrigerated (2–8 °C): Typically 4–8 weeks
- Frozen (-20 °C or below): Up to 3–4 months
To preserve peptide integrity, avoid repeated freeze–thaw cycles, as these may accelerate peptide degradation.
Important: Most manufacturers recommend discarding reconstituted peptides within 4 weeks when stored at 2–8 °C. This recommendation is intentionally conservative and may not reflect the actual chemical stability of every peptide. In our own stability studies, many peptides reconstituted in bacteriostatic water showed no detectable degradation after 12 weeks of refrigerated storage. As peptide stability is highly sequence- and formulation-dependent, this result should not be extrapolated to all peptides without supporting stability data.
Analytical documentation
Tests
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 10mg
99.4%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 9.78 mg
- PurityPeptide screening
- 99.4%
- Identity (FTIR)FTIR spectrum
- 994
- Identity (RT)Retention time
- 0.995
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- 0.082 EU/mg
- Molecular Ion MassMS deconvolution
- 4731 Da
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 20mg
99.4%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 18.87 mg
- PurityPeptide screening
- 99.4%
- Identity (FTIR)FTIR spectrum
- 994
- Identity (RT)Retention time
- 0.996
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- 0.015 EU/mg
- Molecular Ion MassMS deconvolution
- 4731 Da
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Latest published result
Liquilabs s.r.o.Signed Certificate of Analysis · 30mg
99.8%Purity by HPLC
Recorded QC panel
- AssayPeptide screening
- 30.0 mg
- PurityPeptide screening
- 99.8%
- Identity (FTIR)FTIR spectrum
- 994
- Identity (RT)Retention time
- 0.996
- Bacterial EndotoxinUSP / Eur. Ph. 2.6.14
- 0.008 EU/mg
- Molecular Ion MassMS deconvolution
- 4731 Da
These are the latest published results for this strength. The batch number is printed on each vial. Your supplied batch is confirmed against the matching published record when your order is allocated.
Source record
References
Coskun T, Urva S, Roell WC, et al. · 2022
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Discovery, molecular design, and receptor characterisation of LY3437943.
Cell Metabolism · 10.1016/j.cmet.2022.07.013 View source ↗Jastreboff AM, Kaplan LM, Frías JP, et al. · 2023
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Clinical research report concerning the compound described as retatrutide.
The New England Journal of Medicine · 10.1056/nejmoa2301972 View source ↗National Center for Biotechnology Information
PubChem Compound Summary: Retatrutide
Authoritative identity record for retatrutide, also described as LY3437943.
PubChem · View source ↗Goldney J, Hamza M, Surti F, Davies MJ, Papamargaritis D · 2025
Triple Agonism Based Therapies for Obesity
Current cardiovascular risk reports · View source ↗Katsi V, Koutsopoulos G, Fragoulis C, Dimitriadis K, Tsioufis K · 2025
Retatrutide-A Game Changer in Obesity Pharmacotherapy
Biomolecules · View source ↗Abdrabou Abouelmagd A, Abdelrehim AM, Bashir MN, Abdelsalam F, Marey A, Tanas Y, Abuklish DM, Belal MM · 2025
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
Proceedings (Baylor University. Medical Center) · View source ↗· 2025
Retatrutide (LY3437943): A Novel Tri-agonist Peptide for Metabolic Disease Treatment
2025 ·Alaa Abdrabou Abouelmagd et al. · 2025
Efficacy and safety of retatrutide, a novel GLP-1, GIP, and GCG receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials
2025 ·· 2024
Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037–2048. doi: 10.1038/s41591-024-03018-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
· 10.1038/s41591-024-03018-2 View source ↗· 2023
Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and GCG receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi: 10.1016/S0140-6736(23)01053-X. [DOI] [PubMed]
· 10.1016/s0140-6736(23)01053-x View source ↗· 2022
Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and GCG receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. doi: 10.1016/S0140-6736(22)02033-5. [DOI] [PubMed]
· 10.1016/s0140-6736(22)02033-5 View source ↗Customer reviews
Continue exploring
